Saving Hearts In Rural West Texas: Impact Of Critical Care Access On Mortality Rates
The critical access hospital (CAH) designation program was created in 1997 by the US congress with the purpose of reducing the financial vulnerability of rural hospitals and improving the access to healthcare by keeping fundamental services in rural communities. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Rami Al-Ayyubi, Laura Gonzalez-Reyes, Andres Mata, Divya Parepalli, Muhammad Qudrat Ullah, Aimen Dar, Raghavendra Sanivarapu Tags: 015 Source Type: research
Treatment Effects Of Empagliflozin In Hospitalized Heart Failure Patients Across The Range Of Left Ventricular Ejection Fraction - Results From The EMPULSE Trial
The EMPULSE trial recently showed that the sodium-glucose cotransporter 2 inhibitor empagliflozin (10 mg/day) (SGLT2i) improved clinical outcomes of patients who were hospitalized for acute heart failure. In this post-hoc analysis we studied whether the effects were consistent according to the range of left ventricular ejection fraction (LVEF). (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Jasper Tromp, Mikhail Kosiborod, Christiane Angermann, Sean Collins, John Teerlink, Piotr Ponikowski, Jan Biegus, Joao Pedro Ferreira, Michael Nassif, Mitchell Psotka, Martina Br ückmann, Jonathan Blatchford, Dominik Steubl, Adriaan Voors Tags: 016 Source Type: research
The Impact Of Unmet Palliative Care Needs And Physical Frailty On Clinical Outcomes: A Prospective Study Of Adults With Heart Failure
This study sought to examine the association of unmet PC needs and physical frailty with clinical outcomes (baseline HRQOL and hospitalizations or mortality at 6-months). (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Lyndsay DeGroot, Noelle Pavlovic, Nancy Perrin, Sydney M. Dy, Sarah Szanton, Nisha Gilotra, Quin Denfeld, Hailey Miller, Colleen McIlvennan, Patricia Davidson, Martha Abshire Tags: 018 Source Type: research
Formalized Frailty Evaluation Improves Provider Communication And Confidence In Frailty Assessment Of Patients With Advanced Heart Failure
There are currently no standardized objective measures or definition of frailty specific to the advanced heart failure (HF) patient. As a result, the concept of frailty is challenging to communicate across providers and care teams, and utilizing frailty as a definitive criterion for evaluating patient candidacy for advanced HF therapies becomes more difficult. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Brian Hsi, Sanjeeb Bhattacharya, Ran Lee, W.H. Wilson Tang Tags: 019 Source Type: research
Clinical Utility Of An AI-Based Model For Detection Of Heart Failure With Preserved Ejection Fraction Using Decision Curve Analysis
Detection of heart failure with preserved ejection fraction (HFpEF) remains challenging due to indeterminate imaging outputs and discordant clinical features. Existing guidelines and clinical algorithms often produce non-diagnostic outcomes, especially in complicated cases. To address this, we developed an artificial intelligence (AI) model to analyze a single echocardiographic video clip for HFpEF detection. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Ross Upton, Ashley P. Akerman, Mihaela Porumb, Christopher G. Scott, Arian Beqiri, Agisilaos Chartsias, Alexander Ryu, William Hawkes, Geoffrey Huntley, Ayana Arystan, Garvan Kane, Sorin Pislaru, Francisco Lopez-Jimenez, Rizwan Sarwar, Jamie O'Driscoll, P Tags: 020 Source Type: research
Primary Results From APOLLO-B Open-label Extension Study Of Patisiran In Patients With Transthyretin Cardiac Amyloidosis
The Phase 3, placebo-controlled APOLLO-B study (NCT03997383) is evaluating the efficacy and safety of patisiran in patients (pts) with ATTR cardiac amyloidosis in a 12-month (M) double-blind (DB) period followed by an open-label extension (OLE) period when all pts receive patisiran. During the DB period, patisiran demonstrated statistically significant differences vs placebo in change from baseline (CFB) to M12 in 6-minute walk test (6MWT) and KCCQ-OS, and nominal significance in NT-proBNP and troponin I. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Mathew S. Maurer, John L. Berk, Mazen A. Hanna, Julian D. Gillmore, Pedro V. Schwartzmann, Olivier Lairez, Masaru Hatano, Hyun-Jai Cho, Peter van der Meer, Matthew T. White, Elena Yureneva, Marianne T. Sweetser, Patrick Y. Jay, John Vest, Marianna Fontana Tags: 021 Source Type: research
Effect Of J-valve For Treatment Of Native Aortic Regurgitation (NAV) On Left Ventricular (LV) Ejection Fraction (EF) And LV Geometry. A Single Center Compassionate Use Study
Severe aortic regurgitation (AR) is the indication for 20-30% of surgical aortic valve replacements and is associated with increased morbidity and mortality. No transcatheter device has received U.S. approval for the treatment of AR. J-valve is a short frame, self-expanding TAVR device specifically designed for treatment of severe AR (Figure 1A). LV pressure overload can result in alterations of LV geometry. The four resulting categories are: normal, concentric hypertrophy (CH), eccentric hypertrophy (EH), and concentric remodeling (CR). (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Hanad Bashir, Cassady Palmer, Christian Schmidt, Santiago Garcia, Dean J. Kereiakes, Eugene Chung Tags: 022 Source Type: research
Maximizing Heart Transplant Success: Histopathological Insights From Utilization Of Organ Care System For Extended Procurement Distance
The utilization of the Organ Care System (OCS) (Transmedics, Andover, MA) has enabled extension of ex-situ intervals for ex-vivo organ perfusion of the heart allowing for expansion of the limited donor pool to include extended distances. We aimed to compare outcomes and histopathological differences in the utilization of OCS and conventional cold storage technique for donor heart preservation. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Ameesh Isath, Suguru Ohira, Vasiliki Gregory, Avi Levine, Stephen Pan, Gregg Lanier, Chhaya Aggarwal, Kevin Wolfe, David Spielvogel, Masashi Kai, Alan Gass Tags: 024 Source Type: research
Implications Of Dosing IV Loop Diuretic Relative To Home Loop Diuretic In Hospitalized Patients With Decompensated Heart Failure
Intravenous loop diuretics (IVLDs) are crucial to achieve clinical compensation in acute decompensated heart failure (ADHF). The Heart Failure Clinical Research Network studies have proposed dosing IV loop diuretics based on home loop diuretic (HLD) dosing and touted 2.5x dosing may not significantly affect kidney function. However, the risk-benefit assessment of these strategies in real-world setting has not been evaluated. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Michael T. Kimbrell, Jaskeerat Gulati, Lin Zhong, Yiqing Wang, Donghan Yang, Bethany Roehm, Susan Hedayati, Mary Jane Farr, Nicholas Hendren, Mark Drazner, Wai Hong Tang, Justin Grodin Tags: 025 Source Type: research
Survival Of Patients With Monoclonal Gammopathy Of Undetermined Significance And Transthyretin Amyloid Cardiomyopathy
Monoclonal gammopathy of undetermined significance (MGUS) is a precursor plasma cell dyscrasia that has been reported to be present at higher rates in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) when compared to age-matched individuals in the general population. Whether MGUS in ATTR-CM is associated with worse outcomes is unknown. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Mark R. Prasad, Pranav Chandrashekar, Lana Al-Rashdan, Yunwoo Burton, Yuanzi Zhao, Abby Coleman, Rebecca Silbermann, Eva Medvedova, Ahmad Masri Tags: 026 Source Type: research
Real-world Experience Of Adverse Events And Modes Of Failure Related To The New Impella 5.5 - A Retrospective Analysis From Manufacturer And User Facility Device Experience Database
Impella 5.5 with Smart Assist is the newest heart pump that has received U.S. Food and Drug Administration (FDA) pre-market approval in 2019 for safety and efficacy in the therapy of cardiogenic shock for up to 14 days at limited centers in the United States. Impella consists of several different models that vary in caliber, insertion technique, and maximum hemodynamic support capabilities. Impella 5.5 is minimally invasive, implanted via the axillary artery or the anterior aorta eliminating the need for a sternotomy or coring of the left ventricle unlike older versions. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Kripa Rajak, Anupam Halder, Aslan Amirian, Resha Khanal, Anas Atrash, Navitha Ramesh, Rohan Goswami Tags: 027 Source Type: research
Differences In Wait-list Mortality In Patients Bridged With Temporary Or Durable Mechanical Circulatory Support Devices; A Propensity Score Matched Analysis Of The Current Unos Listing System
In the current UNOS heart transplant listing system, priority is given to patients who are on temporary mechanical circulatory support (tMCS), while those on durable left ventricular assist devise (LVAD) support are deemed stable and not prioritized for transplant. Outcomes have significantly improved with the HeartMate 3 (HM3) devices, but it is unclear whether older generation devices, the HeartMate II (HM II) or HeartWare (HVAD) have a survival disadvantage and should be prioritized. The aim of this study is to compare the composite outcome (waitlist mortality and incidence of delisting) between patients on with tMCS an...
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Mahwash Kassi, Salma Zook, Arvind Bhimaraj, Nadia Fida, Syed Ahsan, Janardhana Gorthi, Imad Hussain, Ju Kim, Sapna Legha, Cindy Martin, Salil Kumar, Duc Nguyen, Edward Graviss, Ashrith Guha Tags: 028 Source Type: research
Optimization Of Guideline Directed Medical Therapy Utilizing Standardized Electronic Documentation During Heart Failure Hospitalization
Heart failure is a progressive disease that greatly affects quality of life. This disease is associated with a high 5-year mortality rate, high frequency of hospitalizations and functional limitations. The use of guideline directed medical therapy (GDMT) has been shown to reduce hospitalizations and greatly improve functional status. However, adherence to GDMT and optimization is challenging. We implemented a standardized electronic medical record (EMR) checklist to assure adherence. We conducted a retrospective study with the aim to evaluate the impact of standardized documentation EMR on GDMT adherence. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Gabriela Narowska, Linda Ruppert, Sarah Williams, Sanjana Bhatia-Patel, Carly Fabrizio, Val Rakita, Eman Hamad Tags: 029 Source Type: research
Impact Of Patisiran On Health Status And Quality Of Life In Patients With Transthyretin Cardiac Amyloidosis
APOLLO-B is a Phase 3 study of patisiran in patients with transthyretin (ATTR) cardiac amyloidosis (NCT03997383), which demonstrated a significant benefit in functional capacity (6-MWT), and health status and quality of life (QoL) (KCCQ-OS) with patisiran vs placebo at Month (M) 12. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Zubair Shah, Laura Obici, Parag Kale, Sumeet S. Mitter, Per Eldhagen, Toru Hashimoto, Edileide de Barros Correia, Matthew T. White, Sean Bender, Patrick Y. Jay, Kelley Capocelli, Mazen A. Hanna Tags: 030 Source Type: research
Sleep Abnormalities Among Community Participants At Risk For Heart Failure
Sleep abnormalities are associated with metabolic health and underlying heart failure (HF). HF with preserved Ejection Fraction (HFpEF) is the most common cause of HF but is severely underdiagnosed given the limitations in current diagnostic criteria. Therefore, we sought to determine self-reported and directly recorded sleep abnormalities using custom fitted beds capable of physiological monitoring (SleepNumber Co) among community-dwelling participants who were at risk of HFpEF. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - January 1, 2024 Category: Cardiology Authors: Yogesh N.V. Reddy, Susan DeFranco, John Park, Amir Lerman, Virend Somers, Barry Borlaug Tags: 031 Source Type: research
